11:11 AM EST, 02/27/2025 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) said Thursday it has signed a deal to sell its rare pediatric disease priority review voucher for $150 million, with transaction expected within 30 to 45 days.

Zevra was granted the voucher in September last year following Miplyffa approval by the US Food and Drug Administration.

Shares of the company were up over 4% in recent trading.

Price: 7.75, Change: +0.36, Percent Change: +4.87